A venture capital firm dedicated to bringing bioelectronic medicines to patients.

Action Potential Venture Capital

Action Potential Venture Capital (APVC) is GSK's bioelectronic medicines venture fund.  APVC is focused on the next generation of peripheral neuromodulation medical devices, and invests in companies and technologies that enable the future of targeted and adaptive bioelectronics.

CVRx

Congratulations to the team, investors, founders and clinical trial participants involved with this landmark pivotal study!

More to come, but an exciting day for this novel therapy under investigation for Rheumatoid Arthritis and other autoimmune diseases. 

#intelligentmedicine #bioelectronicmedicine

Big announcements from Cala Health today ⚡️ 🧠
1) 75% of ET patient's now have access to Cala kIQ therapy via CMS's positive coverage determination, and 

2) We are thrilled to name Deanna Harshbarger CEO to lead the company during this exciting next phase of growth and accessibility for essential tremor and parkinson's disease patients! 

#bioelectronicmedicine #electricityasmedicine #essentialtremor #parkinsonsdisease #CMS #Medicare #CEO

Action Potential Venture Capital portfolio company, Exo’s workflow solution is revolutionizing healthcare, streamlining processes, and enhancing patient care.

Since implementing Exo Works™, Wellstar Health System Health System has:

- Seen a remarkable 47% increase in revenue capture. 

- Achieved a 203% rate of return after nine months and broke even in 3 months. 

- Raised its QA percentage from 10% to 100% for all POCUS exams—including those conducted by residents and medical students 

Read more about the power of Exo here: https://lnkd.in/gBbSYReC

#ExoWorks #Exo #POCUS #Ultrasound
#MedicalImaging #HealthTech #MedTech
#FOAMed #MedEd

👏🏽👏🏽 to SetPoint Medical for receiving Breakthrough Designation in #MultipleSclerosis from the FDA.  Given the limitations of traditional molecular medicines in #MS, Action Potential has tremendous hope for the power of SetPoint's vagus nerve microregulator, to potentially remyelinate nerves in patients suffering with MS.  We join the many who are looking forward to clinical evaluation of this #bioelectronic therapeutic approach for a relapsing-remitting patient group.

#msawareness #inflammatoryreflex #neurotech

Suraj Mudichintala shared his perspectives on the broader Neurotech markets along side a distinguished panel with Sara Shnider, Martin Dieck, and JoJo Platt. The future of Neurotech is bright!

Thrilled to see Exo and Cala Health, both Action Potential Venture Capital portfolio companies, recognized on the Medtech Fierce 15!

https://lnkd.in/eUDaU-Nm

#futureofmedicine #bioelectronics #closedloop #imaging #ai

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Apple Mobile Web Clips Icon

HSTS

DMARC

reCAPTCHA

Google

Microsoft Azure DNS

Partner

Imran Eba

Juan-Pablo Mas

Summer Associate Intern

Linda Chinelo Egbosiuba

Senior Associate

Suraj Mudichintala

MD/PhD Candidate

Brian Hsueh

Isaac B. Stoner

Summer Associate

Ali Kight

Jens Eckstein

Director and Managing Partner

CVRx is a medical device company developing implantable technology for the treatment of high blood pressure.

Early Stage Venture Investors with Investments in Pennsylvania

Early Stage Venture Investors with Investments in Dallas, Texas

Venture Stage Investors with Investments in Dallas, Texas

Venture Stage Investors with Investments in New York

GlaxoSmithKline today announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies. 

The fund’s first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases.

The fund complements the work of GSK’s Bioelectronics R&D unit, which was established in 2012 after a two-year effort to seek out and engage the most promising researchers in this emerging area of science. 

The name of the fund comes from electrical signals called action potentials that pass along the nerves in the body. Irregular or altered patterns of these impulses may occur in association with a broad range of diseases. 

GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns. The devices could be designed to interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses that help treat disorders as diverse as inflammatory bowel disease or rheumatoid arthritis; respiratory diseases such as asthma and COPD and metabolic diseases including Type 2 diabetes.

The field of bioelectronic medicines is in its very early stages. GSK’s ambition, through collaboration with scientists globally, is to have the first medicine that speaks the electrical language of our body ready for approval by the end of this decade.“We want to help create the medicines of the future and be the catalyst for this work,” said Moncef Slaoui, chairman of R&D and architect of GSK’s early stage investment strategy. “GSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts.”

Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas:

- New start-up companies that aim to pursue the vision of bioelectronic medicines
- Existing companies with technologies that are interacting with the peripheral nervous system  through first-generation devices that can stimulate or block electrical impulses
- Companies advancing technology platforms that will underpin these treatment modalities

Action Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSK’s Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.

news impact assignment basic	general
public peers	general	Jul 23, 2024 7:17 AM	ab47a704
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	0a46943b
crunchbase profile	general	Oct 28, 2024 2:47 PM	d6b6e81f
li profile	general	Jul 23, 2024 7:17 AM	9a838fac
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	ee7eded4
peers	general	Jul 23, 2024 7:17 AM	bdab087e
news basic	general	Jul 23, 2024 7:17 AM	07253808
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ACTI

COM:ACTIONPOTENTIALVC

Action Potential Venture Capital